6973 Stock Overview
Engages in the research and development of cell therapy technology and products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
U-Neuron Biomedical Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$39.35 |
| 52 Week High | NT$65.80 |
| 52 Week Low | NT$38.00 |
| Beta | 0 |
| 11 Month Change | 0.64% |
| 3 Month Change | -1.63% |
| 1 Year Change | -4.84% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6973 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.9% | -1.0% | 0.8% |
| 1Y | -4.8% | 0.7% | 30.3% |
Return vs Industry: 6973 underperformed the TW Biotechs industry which returned 0.7% over the past year.
Return vs Market: 6973 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6973 volatility | |
|---|---|
| 6973 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6973 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6973's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | www.u-neuron.com |
U-Neuron Biomedical Inc engages in the research and development of cell therapy technology and products in Taiwan. It develops stem cells for the treatment of stroke with autologous stem cell transplantation The company was founded in 2015 and is based in New Taipei City, Taiwan.
U-Neuron Biomedical Inc Fundamentals Summary
| 6973 fundamental statistics | |
|---|---|
| Market cap | NT$1.16b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6973 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6973 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6973 perform over the long term?
See historical performance and comparison